Increased plasma cyclic nucleotide concentrations in congestive heart failure.

K Ogawa, H Shiozu, K Mizuno, M Ban, T Ito, T Satake

Plasma concentrations of cyclic nucleotides (adenosine monophosphate (AMP) and guanosine monophosphate (GMP) were measured by an ultrasensitive radioimmunoassay in 138 patients with heart failure due to various causes. Measurements were related to the New York Heart Association classification of symptoms, plasma noradrenaline concentrations, and mean pulmonary artery pressures. Serial concentrations of cyclic AMP and GMP were also measured daily in four patients treated for acute left ventricular failure. Plasma concentrations of cycle AMP were related to the severity of the heart failure, plasma noradrenaline concentrations, and pulmonary artery pressures. Cyclic AMP concentrations fell rapidly after treatment of acute left ventricular failure. Plasma concentrations of cyclic GMP also depended on the severity of heart failure and the pulmonary artery pressure, and decreased sharply with treatment although remaining at a high value. The cyclic GMP concentrations were significantly higher in patients with mitral stenosis than in those with other types of heart failure.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Rademaker, M. T., Charles, C. J., Richards, A. M. (2007). Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure. Am. J. Physiol. Heart Circ. Physiol. 293: H1536-H1544 [Abstract] [Full Text]  
• Rademaker, M. T., Cameron, V. A., Charles, C. J., Richards, A. M. (2005). Integrated Hemodynamic, Hormonal, and Renal Actions of Urocortin 2 in Normal and Paced Sheep: Beneficial Effects in Heart Failure. Circulation 112: 3624-3632 [Abstract] [Full Text]  
• Rademaker, M. T., Charles, C. J., Espiner, E. A., Frampton, C. M., Lainchbury, J. G., Richards, A. M. (2005). Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 26: 2055-2062 [Abstract] [Full Text]